Endothelial Activation Response to Oral Micronised Flavonoid Therapy in Patients with Chronic Venous Disease – a Prospective Study  by Shoab, S.S et al.
Eur J Vasc Endovasc Surg 17, 313–318 (1999)
Article No. ejvs.1998.0751
Endothelial Activation Response to Oral Micronised Flavonoid Therapy in
Patients with Chronic Venous Disease – a Prospective Study
S. S. Shoab*, J. Porter, J. H. Scurr and P. D. Coleridge-Smith
Department of Surgery, University College London Medical School, London, U.K.
Background: endothelial activation is important in the pathogenesis of skin changes due to chronic venous disease
(CVD). Purified micronised flavonoid fraction has been used for symptomatic treatment of CVD for a considerable period
of time. The exact mode of action of these compounds remains unknown.
Aim: to study the effects of micronised purified flavonoidic fraction (Daflon˛ 500 mg, Servier, France) treatment on
plasma markers of endothelial activation.
Materials and methods: twenty patients with chronic venous disease were treated for 60 days with DAFLON˛ 500 mg
twice daily. Duplex ultrasonography and PPG was used to assess the venous disease. Blood was collected from a foot
vein immediately before starting treatment and within 1 week of stopping treatment. Plasma markers of endothelial
activation were measured using commercial ELISA kits.
Results: reduction in the level of ICAM-1, 32% (141 ng/ml: 73 ng/ml) and VCAM 29% (1292 ng/ml: 717 ng/ml) was
seen. Reduction in plasma lactoferrin (36% decrease, 760 ng/ml: 560 ng/ml) and VW factor occurred in the C4 group
only.
Conclusions: micronised purified flavonoidic fraction treatment for 60 days seems to decrease the levels of some plasma
markers of endothelial activation. This could ameliorate the dermatological effects of (CVD). This could also explain some
of the pharmacological actions of these compounds. Our study demonstrates the feasibility of using soluble endothelial
adhesion molecules as markers for treatment.
Introduction Pharmacological treatment is widely used to ameli-
orate the symptoms of venous disease in many Euro-
Chronic venous disease (CVD) and its sequelae are a pean countries. It is hardly used in other places. One
major cause of morbidity in the Western world.1,2 The reason for these discrepancies is the lack of controlled
inflammatory response seen in CVD involves leucocyte scientific trials establishing the role of these com-
and endothelial adherence, cell activation and cell pounds. At least one recent study shows increased
migration. This involves adhesion molecule expression ulcer healing rates in response to flavonoid treatment.4
by endothelial cells, leucocyte activation and local Unfortunately, no “phlebotonic” drugs exist that claim
cytokine activity. Currently there are no studies re- to correct venous valvular incompetence. However,
garding the changes in these endothelial markers fol- many of these do affect the inflammatory changes
lowing therapy for CVD. responsible for the skin damage.
Endothelial cell activation by cytokines or thrombin The response of the increased endothelial activation
leads to increased adhesion molecule expression. These to any form of therapy remains unknown. The medical
include ICAM-1 (binds neutrophil/lymphocytes) and compounds that have been used for treating venous
VCAM-1 (binds lymphocytes/monocytes). This can disease include flavonoids (diosmin/hydoxyethyl-
lead to MHC-II (T-cell response) and GMP-140 (binds rutosides), methyl-xanthines, prostaglandin and fib-
platelets) expression. Binding of platelets increases the rinolytics amongst others. A purified micronised fla-
availability of platelet-activating factor and further vonoid fraction (Daflon˛500, Servier Laboratories,
accelerates the expression of adhesion molecules. The France) has been used in Europe for the treatment of
circulating levels of many of these molecules are CVD for some time. Daflon consists of 90% Diosmin (3¢,
known to be increased in patients with CVD.3 5,7 trihydroxy-4¢-methoxyflavone 7 rhamnoglucoside;
C28H32O15) and 10% hesperidin flavonoids (3¢,5,7* Please address all correspondence to: S. S. Shoab, Department of trihydroxy-4¢-methoxylflavone 7 rhamnoglucoside,Surgery, 1st Floor, Jules-Thorne Building, The Middlesex Hospital,
Mortimer Street, London W1N 8AA, U.K. C28H34O15). The use of pharmacological treatment is
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Table 1. Distribution of the patients according to their CEAP stage and anatomical localisation of CVD.
There are equal numbers of patients with and without skin changes (n=10). Two patients had reflux localised
to “minor” tributaries that did not relate to either of the two major superficial systems. Perforator incompetence
is not listed separately because none of the patients had isolated perforator incompetence.
SVI DVI SVI/DVI LSV SSV LSV/SSV Other
C2 3 — — 2 1 1 1
C3 4 — 3 2 — 2 1
C4 7 1 2 5 — 4 —
Median age 58 14 (2m:12f) 1 (m) 5 (3m:f) 9 (3m:f) 1 (f) 7 (3m:4f) 2 (f)
(range 39–82)
IL-1 and IL-6
ICAM-1 E-selection
(ELAM-1)
VCAM-1
Endothelial cells
VW-factor
Platelet activation
Platelet activating
factor
Monocyte
Leucocyte mediated injury
induces IL-1, TNF-a  and
TGF-b
LymphocyteNeutrophil
Fig. 1. Chronic venous disease leads to a microangiopathy. This involves adhesion molecule expression by endothelial cells, leucocyte
activation and local cytokine activity. Endothelial cell activation by cytokines or thrombin leads to increased adhesion molecule expression.
This includes ICAM-1 (binds neutrophils/lymphocytes), VCAM-1 (binds lymphocytes/monocytes) and E-selectin (ELAM-1). MHC-II (T-
cell response) and GMP-140 (binds platelets) expression can occur. Binding of platelets increases the availability of platelet-activating
factor and further accelerates the expression of adhesion molecules. The circulating levels of many of these molecules are known to be
increased in patients with CVD.
variable, mainly because of lack of good controlled soluble markers of endothelial activation in CVD. In
addition plasma lactoferrin levels were studied as atrials. There is evidence of increased healing rate of
venous ulcers with Daflon.5 marker of neutrophil degranulation.7
Daflon˛ comprises 450 mg of diosmin and 50 mg
of hesperidin per tablet. The “micronisation” of the
effective components increases its bio-availability. It
has been reported to be a “venotonic” (increases ven- Materials and Methods
ous tone!) and to decrease capillary “leakage” in many
scenarios. A double-blind randomised trial published Evaluation
in 1994 had shown its efficacy in treating the clinical
symptoms of CVD without any significant side-effects.6 Ethics committees’ consent for the study was obtained
from UCL Medical School Committee for medicalThe aim of our study was to study the effects of
micronised purified flavonoid fraction (S5682, Daflon˛ ethics. Patients with chronic venous disease, clinical
stage 2–4, were recruited from the vascular clinic at500 mg, Servier, France) treatment on expression of
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Table 2. Median values of plasma levels of endothelial activation markers and plasma lactoferrin in patients with CVD. Data obtained
for patients with simple CVD (C2–3) and those with dermatological changes (C4) is shown. The values are before and after a 60-d
treatment with oral purified micronised fraction (parenthesis=IQR).
ICAM-1 VCAM VW Factor SE-Selectin Sp-Selectin Lactoferrin
(lg/ml) (ng/ml) % activity (ng/ml) (ng/ml) (lg/ml)
All patients Before 141 1292 65 49 74 690
treatment (102–162) (950–1500) (45–105) (31–61) (57–97) (373–760)
After 73 717 65 36 90 494
treatment (65–93) (625–1156) (50–105) (28–59) (55–120) (350–715)
Significance <0.001 <0.001 0.88 0.156 0.09 0.231
(Wilcoxon)
C2–C3 Before 109 1300 50 41 78 420
treatment (91–136) (1140–1500) (40–77) (33–61) (58–97) (32–660)
After 68 800 78 36 80 420
treatment (62–78) (625–11250) (51–109) (30–47) (53–1101) (350–520)
Significance 0.001 0.001 0.012 0.1 0.74 0.59
(Wilcoxon)
C4 Before 153 1075 65 50 77 760
treatment (120–186) (913–1513) (51–105) (27–63) (58–96) (635–1000)
After 78 880 58 31 100 560
treatment (72–106) (675–1231) (50–75) (25–60) (72–125) (380–800)
Significance 0.001 0.003 0.039 0.61 0.54 0.027
(Wilcoxon)
urea and electrolyte/liver function tests. All patients
were assessed clinically according to the clinical classi-
fication of the Hawaii system. People with (duplex
proven) varicose veins only (C2), with associated oed-
ema (C3), skin changes (C4) and/or healed ulceration
(C5) of >4 weeks were included. Active ulceration (C6)
would have interfered with activation of leukocytes
and these were thus not included.
All patients had a venous duplex examination and
photoplethysmography within the previous 8 weeks to
establish venous disease and to localise it anatomically.
The minimum extent of duplex examination in
our patients included saphenofemoral junction, long
saphenous vein, saphenopopliteal junction, short
saphenous vein, anatomical perforators. Femo-
ropopliteal veins and other reflux sites as picked up
by colour Doppler. Patients were assessed for other
possible diagnoses, including arterial disease. Ankle–
brachial pressure ratios were performed whenever
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there was clinical suspicion. All patients wore class II
Fig. 2. Changes in plasma levels of ICAM-1 and VCAM-1 in patients support stockings and continued to do so during thewith CVD before (A) and after (B) 60-d treatment with micronised
study.purified flavonoid fraction. A logarithmic scale has been used
because of the differences in the absolute levels of the two molecules.
p levels are Wilcoxon ranked-sum test. The thick lines join the
respective median levels. Vertical lines represent interquartile range.
Patient selection
the Middlesex Hospital. Patients who consented were
asked to attend the department on three separate The inclusion criteria for the study were: (1) age above
18 years; (2) patients affected with Hawaii stage C2 tooccasions at 2 weeks before treatment, the day of
starting treatment and after finishing treatment. A C4; (3) C6 with a healed ulcer for at least 4 weeks,8
(4) psychological stability and motivation.medical history was taken and clinical examination
performed. This included a systemic as well as venous
The exclusion criteria were directed at: (i) patients whoexamination. Patients had a full blood count, serum
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Table 3. Comparison of mean visual analogue symptom scores in all patients before and
after 60-d treatment with “purified micronised flavonoid fraction”. Although decrease
was seen in all the parameters, only the decrease in “heaviness” reached statistical
significance. (Values in parentheses are standard deviation).
Pain Heaviness Cramps Paraesthesiae Oedema
Before treatment 8.2 (3.3) 7.7 (2.6) 8.1 (2.8) 5 (3.3) (6.8 (3.2)
After treatment 8.2 (3.3) 6.4 (2) 6.8 (3.4) 4.8 (2.8) 5.8 (2.4)
Probability 0.094 0.004 0.07 0.19 0.057
(Wilcoxon)
(NSAIDs), other “vaso-active” drugs, Vitamins A, C
and E or anticoagulants; (12) previous poor compliance
to treatment; (13) participants of a trial within past 3
months were excluded; (14) pregnancy, breastfeeding
or lack of active contraception also excluded the
patient.
Daflon˛ 500 mg twice daily (Servier, France) was
administered for 60 days. Evaluation of venous symp-
toms employing a visual analogue scale was performed
before and after treatment. Specimens (30 ml each)
were taken from foot veins before and after standing
the patient supported for 30 min.
Collection of specimens
A 18G cannula (Vasculon 2, Viggo-Spectramed, Hel-
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sinborg, Sweden) was placed in the distal long sa-
Fig. 3. Shows the differing changes in plasma lactoferrin in patients phenous vein or dorsal foot vein of one leg. The
with (C4) and without (C2–3) skin changes before (A) and after cannula was flushed with heparinised saline solution.(B) 60-d treatment with micronised purified flavonoid fraction.
The patient then stood supported against the side ofProbability levels are Wilcoxon ranked-sum test. The much increased
plasma lactoferrin activity is lowered significantly in patients with the couch for 30 min without moving the calf muscles
skin changes. (it was previously shown by the authors by direct
pressure measurement that this raises the venous pres-
have conditions that would change the status of leu- sure in the superficial veins of the leg to between 70
kocyte/endothelial activation; (ii) subjects who were and 80 mmHg), after which 2 ml of blood was taken
taking compounds similar to flavonoids to avoid bias and discarded from the cannula, and a further 10 ml
and (iii) patients who had other major systemic ill- was collected into two tubes containing ethylene-
nesses. These criteria were: (1) history of alcohol or diamine <TK; 4 tetra-acetic acid and one tube con-
drug abuse; (2) known history of allergy or intolerance taining citrate <TK; 1 (Vacutainer Becton Dickinson
to diosmin or any other venotonic agent; (3) active Vacutainer Systems Europe, BP No 37-38341 Meylan
venous ulceration; (4) diabetes mellitus; (5) impaired Cedex, France). Blood samples were carefully placed
hepatic function (ALT or AST 3-fold above the normal directly into the sample tubes after removing the
limit) or impaired renal function (serum creatinine stoppers to prevent excessive cell agitation.
>120 lmol/l); (6) any concomitant active disease or
abnormality in laboratory test ( judged as clinically
significant by the investigator); (7) patients treated
with other vasoactive drugs within the 15 days prior ELISA tests for soluble markers
to inclusion; (8) patients with an acute/chronic in-
flammatory or infectious disease; (9) deep venous Blood for ELISA tests for soluble plasma markers was
collected in EDTA bottles. The specimens were spunthrombosis within the past 12 months; (10) superficial
venous thrombosis within 3 weeks; (11) patients at 20,000 r.p.m. for 10 min to separate the plasma and
promptly frozen at -20 °C before analysis. Theusing steroids, non-specific anti-inflammatory drugs
Eur J Vasc Endovasc Surg Vol 17, April 1999
Endothelial Activation Response in Oral Micronised Flavonoid Therapy in CVD 317
Markers measured were E-selectin, P-selectin, VCAM, monocytes and lymphocytes were decreased sig-
nificantly. This effect was seen in all patients, ir-ICAM-1, VW factor and lactoferrin. Commercial kits
were used for these tests (ICAM-1/VCAM/E-selectin respective of their clinical stage. Lactoferrin levels were
appreciably reduced following therapy in patients withby R&D Systems, 4–10 The Quadrant, Barton Lane,
Abingdon, Oxon OX14 3YS, U.K.; VW factor kit by skin changes only. This probably represents damping
of the much-increased granulocyte activity in theseDiagnostica Stago, 9 rue des Freres Chausson, 92600
Asniere`s-sur-Seine, France; lactoferrin assay by OXIS patients compared to those with simple CVD. The
effect on E-selectin levels was also seen more in theInternational, Portland, OR, U.S.A.) were used for
these analyses. C4 group. Unknown effects on platelet activity might
explain the slight rise seen in P-selectin following
therapy. Similar effects may explain the differing phe-
nomena seen with VW factor following therapy (riseDemographics
in VW factor in C3 patients and fall in C4 group).
We did not make any distinction between patientsThere were equal numbers of patients with and with-
with superficial venous insufficiency and those without skin changes (n=10). Seven patients in each group
deep venous insufficiency in interpreting the results.had superficial venous insufficiency (SVI). Of the re-
Previous studies from this department did not reportmaining six patients the majority (5) had combined
on any difference between these two groups9 for aSVI and deep venous insufficiency (DVI). Most patients
similar clinical stage. We compared equivalent clinicaleither had long saphenous (LSV) involvement (n=9)
stages (C) which are representative of the severity ofor combined LSV and short saphenous (SSV) in-
CVD. Some of these markers, especially VW factors, arevolvement (n=7). Two patients had CVD involving
not very sensitive indicators of endothelial activation.neither of the two major superficial anatomic systems.
Some, like P-selectin and VW factor, are almost cer-These patients had other superficial veins (e.g. lateral
tainly affected by other local phenomena like plateletsuperficial vein of the thigh) involvement without
activation. The physiological significance of these sol-reflux in the mentioned major superficial systems.
uble markers remains an issue of debate. They may
represent protease cleavage from cell surface sub-
sequent to endothelial stimulation. They may also
Results represent molecules released to block receptors and
to prevent their attachment to the endothelium.
Significant reduction was seen in plasma levels of It is only relatively recently that the effectiveness
VCAM and ICAM-1 activity following therapy. Re- of therapy for CVD is being tested with objective
duction in the level of ICAM-1 32% (141 ng/ml: 73 ng/ parameters. It has been shown that colour-duplex
ml) and VCAM, 29% (1292 ng/ml: 717 ng/ml) were ultrasonographic and air-plethysmographic criteria
seen. Reduction in plasma lactoferrin (36% decrease, improve in patients 1 month following surgical ther-
760 ng/ml: 560 ng/ml) occurred in the skin-changes apy. This improvement was shown to be maintained
group. The levels of VW factor also decreased in at 2 years.10 It would be interesting to measure the
patients with skin changes but not in simple venous mid to long-term effect of therapy on endothelial
disease. markers. Another study of the effect of compression
Changes in E-selectin levels (decrease) and P-selectin therapy/scleropathy on the microangiopathy (Leu et
levels (some increase following therapy) were not al.)11 showed non-significant changes post-therapy. The
significant statistically. The levels of reduction in endo- parameters studied were capillary microscopy, Dop-
thelial markers following flavonoid therapy was seen pler fluxmetry and tcPo2 measurement. Elevated levels
to be similar in each of the different supine– of VCAM-1, VW factor, E-selectin, IAM-1 and lac-
standing–supine positions. toferrin have been reported in patients with CVD
compared to controls.12 However, our study is the
first to demonstrate a measurable change in these
Discussion parameters in CVD following therapy. This shows the
feasibility of using the soluble markers of endothelial
We observed a decrease in some soluble endothelial activation as a parameter to measure the response to
activation markers in patients with CVD following various forms of treatment.
60 d therapy with oral purified flavonoid fraction. In Experimental blockade of adhesion molecules either
particular VCAM-1 and ICAM-1, adhesion molecules with soluble ligands or with specific monoclonal anti-
bodies has a dramatic effect on inflammation andimportant in endothelial interaction with neutrophil,
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2 Nelze´n O, Bergqvist D, Lindhagen A, Hallbo¨o¨k T. Chronicimmune mediated tissue damage.13,14 The observation
leg ulcers: an underestimated problem in primary health carethat some markers are specifically lowered following among elderly patients. J Epidemiol Community Health 1991; 45:
therapy in patients with skin changes demonstrates 184–187.
3 Shields D, Sahary M. White cell activation. In: Coleridge-Smith,the possibility of flavonoids to ameliorate and/or ar-
PD, ed. Microcirculation in Venous Disease. 2nd edition, Austin,rest some of the skin damage that occurs in CVD. TX: Landes BioScience, 1998; 141–174.
Inflammatory mechanisms have been implicated in the 4 Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F,
Debure C et al. Efficacy of Daflon 500 mg in venous leg ulcervalvular damage seen in CVD,15 and these compounds
healing: a double-blind, randomised, controlled versus placebomay have a role in ameliorating this damage as well. trial in 107 patients. Angiology 1997; 48: 77–85.
These aspects merit further study. 5 Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F,
Debure C et al. Efficacy of Daflon 500 mg in venous leg ulcerFurther studies are needed to assess the role of
healing: a double-blind randomised, controlled versus placebosoluble endothelial markers in prognosticating the
trial in 107 patients. Angiology 1997; 48: 77–85.
clinical course of CVD. The role of purified micronised 6 Gilly R, Pillion G, Frileux C. Evaluation of a new micronised
flavonoid fraction (S5682) in symptomatic disturbances of theflavonoid fraction and similar compounds also needs
venolymphatic circulation of the lower limb. A double-blindto be re-examined in the context of non-surgical treat-
placebo controlled study. Phlebology 1994; 9: 67–70.
ment for CVD. 7 Shields DA, Andaz S, Abeysinghe RD, Porter JB, Scurr JH,
Experimentally, flavonoids have been shown to have Coleridge-Smith PD. Plasma lactoferrin as a marker of whitecell
degranulation in venous disease. Phlebology 1994; 9: 55–58.several anti-inflammatory actions. Our study is the
8 Porter JM, Moneta GL. Reporting standards in venous disease:first to demonstrate a mode of action for these com- An update. J Vasc Surg 1995; 21: 635–645.
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PD. Leucocyte activity in the microcirculation of the leg inpouch, Daflon˛ significantly inhibited the macro-
patients with chronic venous disease. J Vasc Surg 1997; 26:molecular permeability-increasing effect of histamine, 265–273.
bradykinin and LTB4. Flavonoid-treated animals also 10 Padberg FT, Pappas PJ, Araki CT, Back TL, Hobson RW.
Hemodynamic and clinical improvement after superficial veintended to have a lower number of leukocytes adhering
ablation in primary combined venous insufficiency with ul-to the venular endothelium.16 In addition flavonoids
ceration. J Vasc Surg 1996; 24: 711–718.
could decrease the production of free radicals17 and 11 Leu AJ, Yanar A, Geiger M, Franzeck UK, Bollinger A.
Microangiopathy in chronic venous insufficiency before andalter cytokine release.18 They can alter the composition
after sclerotherapy and compression treatment: Result of a oneof the venous wall19 and have some haemorrheological
year follow-up study. Phlebology 1993; 8: 99–106.effects.20 Our study demonstrates the effect of mi- 12 Shields D, Saharay M. White cell activation. In Coleridge-
cronised purified flavonoid fraction on decreasing Smith, ed. Microcirculation in Venous Disease 2nd Ed. Austin, TX:
Landers Bioscience, 1998; 141–174.leucocyte degranulation and endothelial activa-
13 Mulligan MS, Paulson JC, De S, Zheng ZL, Lowe JB, Ward PA.tion. The effects of these compounds on duplex Protective effect of oligopolysaccharides in P-selectin-dependent
ultrasonographic parameters and on resolution of lung injury. Nature 1993; 34: 149–151.
14 Vedder NB, Winn RK, Rice CL, Clei EY, Arfors KE, Harlanlipodermatosclerosis need to be quantified in
JM. Inhibition of leucocyte adhesion by anti-CD 18 monoclonalprospective studies. The lack of side-effects of these
antibody attenuates in the rabbit ear. Proc Natl Acad Sci USA
compounds makes them especially attractive as med- 1990; 87: 2643–2646.
15 Ono T, Bergan JJ, Schmid-Schonbein GW, Takase S. Monocyteications for CVD.
infiltration into venous valves. J Vasc Surg 1998; 27: 158–166.In conclusion, the increase in some endothelial ac-
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on the proliferation of normal and abnormal human lymphocytesdomised trials are needed to assess the role of these
and their secretions of interleukin-2. Cancer Letters 1993; 69(3):compounds in CVD. Our study demonstrates the feas- 191–196.
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